MindBio Therapeutics Corp.
MBIO
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -200.48% | -201.55% |
| Total Revenue | -- | -- | -- | -200.48% | -201.55% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -200.48% | -201.55% |
| SG&A Expenses | 909.59% | 463.56% | 212.46% | -87.68% | -84.16% |
| Depreciation & Amortization | -318.53% | 400.00% | 350.00% | -106.06% | 6,575.00% |
| Other Operating Expenses | -3.93% | -3.93% | -44.20% | -44.20% | -44.20% |
| Total Operating Expenses | 784.84% | 441.69% | 193.39% | -87.13% | -82.39% |
| Operating Income | -560.36% | -438.71% | -191.98% | 60.80% | 74.93% |
| Income Before Tax | -868.91% | -1,339.62% | -563.20% | 55.98% | 84.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -868.91% | -1,339.62% | -563.20% | 55.98% | 84.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -237.50% | 100.00% | -150.00% | 1,500.00% | 1,100.00% |
| Net Income | -875.52% | -1,336.26% | -563.65% | 56.12% | 84.82% |
| EBIT | -560.36% | -438.71% | -191.98% | 60.80% | 74.93% |
| EBITDA | -4,564.79% | -1,092.19% | -687.62% | -186.49% | 145.55% |
| EPS Basic | -460.15% | -283.12% | -117.70% | 8.12% | 86.04% |
| Normalized Basic EPS | -320.55% | -158.58% | -26.16% | 52.87% | 85.37% |
| EPS Diluted | -460.15% | -283.12% | -117.70% | 8.12% | 86.04% |
| Normalized Diluted EPS | -237.99% | -158.58% | -26.16% | 52.87% | 85.37% |
| Average Basic Shares Outstanding | -97.08% | 12,126.41% | 12,071.01% | 7,235.39% | 8,503.60% |
| Average Diluted Shares Outstanding | -95.07% | 12,126.41% | 12,071.01% | 7,235.39% | 8,503.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |